Scicchitano Pietro, Cinelli Assunta, Citarelli Gaetano, Livrieri Anna, Campanella Cosimo, De Palo Micaela, Caldarola Pasquale, Ciccone Marco Matteo, Massari Francesco
Cardiology Section, Hospital "F. Perinei", 70022 Altamura, Italy.
Emergency Unit, Hospital "F. Perinei", 70022 Bari, Italy.
Biomedicines. 2025 Jul 29;13(8):1844. doi: 10.3390/biomedicines13081844.
Patients with acute heart failure (AHF) often receive initial non-invasive ventilation (NIV). This study aimed to evaluate the prognostic role of NIV in patients hospitalized for AHF. This was a retrospective cohort study. We enrolled patients admitted to our cardiac intensive care unit with a diagnosis of AHF. Anthropometric, clinical, pharmacological, and instrumental assessments were collected. Both in-hospital and 180-day post-discharge mortality were evaluated. Among 200 patients (mean age 81 ± 9 years; 52% male), NIV was applied in 80 cases (40%). These patients had more severe NYHA functional class, a higher prevalence of de novo AHF, required higher diuretic doses, and had longer hospital stays. In multivariate analysis, NIV remained significantly associated with length of stay (LOS) (r = 0.26; = 0.0004). In-hospital mortality was 5% overall and significantly higher in the NIV group compared to non-NIV patients (10% vs. 1.6%, < 0.001). At 180 days, mortality was also significantly higher in the NIV group [hazard ratio (HR) 1.84; 95% confidence interval (CI): 1.18-2.85; = 0.006]. After adjusting for age, BNP, CRP, arterial blood gas parameters, renal function, and LVEF, NIV remained an independent predictor of 180-day mortality (HR 1.61; 95% CI: 1.01-2.54; = 0.04). Patients with AHF who required NIV exhibited more severe disease and longer hospital stays. NIV use was independently associated with both in-hospital and post-discharge mortality, suggesting its potential role as a prognostic marker in AHF.
急性心力衰竭(AHF)患者常接受初始无创通气(NIV)治疗。本研究旨在评估NIV在因AHF住院患者中的预后作用。这是一项回顾性队列研究。我们纳入了入住我院心脏重症监护病房且诊断为AHF的患者。收集了人体测量学、临床、药理学和器械评估等数据。评估了住院期间及出院后180天的死亡率。在200例患者(平均年龄81±9岁;52%为男性)中,80例(40%)应用了NIV。这些患者的纽约心脏协会(NYHA)功能分级更严重,新发AHF的患病率更高,需要更高剂量的利尿剂,且住院时间更长。多因素分析显示,NIV与住院时间(LOS)仍显著相关(r = 0.26;P = 0.0004)。总体住院死亡率为5%,NIV组显著高于非NIV患者(10%对1.6%,P < 0.001)。在180天时,NIV组的死亡率也显著更高[风险比(HR)1.84;95%置信区间(CI):1.18 - 2.85;P = 0.006]。在调整年龄、脑钠肽(BNP)、C反应蛋白(CRP)、动脉血气参数、肾功能和左心室射血分数(LVEF)后,NIV仍是180天死亡率的独立预测因素(HR 1.61;95% CI:1.01 - 2.54;P = 0.04)。需要NIV的AHF患者疾病更严重,住院时间更长。使用NIV与住院期间及出院后死亡率均独立相关,提示其在AHF中作为预后标志物的潜在作用。